TMAN opens Heaven Herb factory, moves into Longevity market, targets 5-10% of revenue within 3-5 years

Kaohoon··TH·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

T. Man Pharmaceutical Public Company Limited, or TMAN, has announced it is building a New S-Curve in the Health & Wellness business group through Longevity innovation via the Heaven Herb factory, one of the group's most fully integrated production bases. Chief Executive Officer Praphon Thanachotiphan revealed that the five-year business plan will deliver approximately 15 Science-backed Longevity Solutions products (SKUs), covering metabolic and cellular systems, gut health and inflammation, brain and sleep, as well as skin health. Over the next 3-5 years, the company aims to generate 5-10% of its portfolio revenue from this group, making it a new Growth Engine for the organisation. The company estimates Thailand's Healthcare market value in 2026 at approximately 37.65 billion US dollars, and expects it to rise to approximately 61.38 billion US dollars in 2033, growing at an average of 8.49% per year. Chief Operating Officer Tras Absuwan said the Heaven Herb factory operates on a fully integrated basis, from extracting active substances from herbs to developing and processing them into herbal products, dietary supplements and cosmetics under GMP PIC/S, ISO 22716 and ISO 22000 standards, with a plan to fully transform into a Smart Factory and to operate under an ESG framework. It has received Level 2 Green Industry certification and a Level 3 White Factory award.

Impact on assets 1

Health Care▲ · 1 stocks
T Man Pharmaceutical PCL
TMAN
▲ PositiveTechnologyrelevance

TMAN opens the fully integrated Heaven Herb factory and launches ~15 Science-backed Longevity SKUs, a new product/R&D-driven growth engine targeting 5-10% of revenue.

Theme Impact 1

Related news

United States
▲

Longevica Forms Scientific Advisory Board to Advance Longevity Pipeline

Longevica Therapeutics announced the formation of its Scientific Advisory Board, marking the preclinical biotech's pivot from foundational discovery to clinical execution and drug development. The company invested four years and $13 million in what it calls the world's largest in vivo mammalian screening program at The Jackson Laboratory, tracking 1,033 small-molecule compounds across more than 16,000 subjects over their natural lifespans. From that screen, 60-plus compounds extended mammalian lifespan by over 10% to 22%, and the company is now pursuing two novel classes of health-and-lifespan therapeutics alongside targeted drug repurposing for cardiovascular, metabolic, fibrotic, and systemic disease. The advisory board spans scientific, clinical, strategy, and business roles, including Dr. Steven Garan of UC Berkeley as Chief Scientific and Technology Advisor, Dr. Mike Zack as Chief Medical and Scientific Advisor, and Allan Gobbs of ATEM Capital as Corporate Strategy and Finance Advisor. The move follows the recent appointment of former Genentech, Roche, and NCI/NIH leader Dr. Prasun Mishra as Chief Executive Officer.
New China Life…ROP.SW
Longevity & Life Extension ▲
About megatrends
Longevity & Life Extension › Metabolic Aging & Geroprotectors ▲Technology
Longevica Therapeutics · Technology · Positive Longevica formed a Scientific Advisory Board to advance its longevity drug pipeline from preclinical discovery to clinical execution, with 60-plus compounds extending mammalian lifespan.
Read original ↗
Business Wire·8dRead more →

Animal Longevity Summit to hold first global scientific forum on healthy aging in animals

The Animal Longevity Summit has announced its inaugural two-day scientific conference, taking place October 1–2, 2026, in Toronto. The event will bring together leading experts in geroscience, veterinary medicine, biotechnology, and aging research to explore how the biology of aging can be measured, slowed, and translated into longer, healthier lives, beginning with animals. The summit arrives as landmark initiatives such as the Dog Aging Project and a growing number of veterinary clinical trials generate the first large-scale datasets on interventions to improve healthspan and longevity in companion animals. The conference program will feature eight scientific tracks covering canine longevity, comparative biology of aging, biomarkers, longevity interventions, veterinary geroscience, cross-species translation to human health, and emerging research from early-career scientists. The inaugural speaker lineup includes Dr. Matt Kaeberlein of the Dog Aging Project, Dr. Vera Gorbunova of the University of Rochester, Dr. Aubrey de Grey of the LEV Foundation, Dr. Varun Dwaraka of TruDiagnostic, Liz Parrish of BioViva, and Dr. Raghav Sehgal of Yale, with additional speakers to be announced. Industry participation is also expected, with Genflow Biosciences confirming it will present new findings from its SLAB study investigating gene therapy in aged beagles.
GENF.LSE ▲
Longevity & Life Extension ▲
About megatrends
Longevity & Life Extension › Longevity Diagnostics & Aging Clocks ▲Demand
Longevity & Life Extension › Metabolic Aging & Geroprotectors Technology
GENF.LSE · Demand · Positive Genflow will present new SLAB study findings at the summit, highlighting its gene therapy for aged beagles.
Read original ↗
GlobeNewswire·68dRead more →
© 2026 MarketIVNews